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Background: The Medtronic CoreValve® with Accutrak delivery system (MCVAT)
(Medtronic Inc., Minneapolis, MN) was introduced to aid deliverability. The aim was to
compare short-term outcomes after transcatheter aortic valve implantation (TAVI) with
both the original Medtronic CoreValve® delivery system (MCV) vs. the MCVAT.
Methods: All consecutive patients with native valve aortic stenosis undergoing trans-
femoral TAVI in our center from November 2007-May 2012 with either MCV or
MCVAT were included. The 31 mm MCVAT became available in September 2011.
Study objectives were the Valve Academic Research Consortium (VARC) outcomes.
Results: In total, 125 TAVI cases were included: 56% (n70) MCV and 44% (n55)
MCVAT. There was a trend for patients treated with MCV to be older (79.76.7 vs.
77.56.9 years; p0.072), but no other differences in baseline characteristics. Logistic
EuroSCORE was respectively 24.616.5% in MCV vs. 24.015.6% in MCVAT
(p0.569) and STS score 9.39.6% vs. 8.78.2% (p0.713). At 30 days, there were no
differences between MCV and MCVAT respectively in all-cause (7.1% vs. 5.6%;
p0.721) or cardiovascular mortality (2.9% vs. 5.6%; p0.449). In addition, myocardial
infarction (2.9% vs. 0%; p0.206) and stroke (0 vs. 1.8%; p0.257) were similar.
However, there were improvements in major vascular complications (17.1% vs. 3.6%;
p0.017), life-threatening bleeding (32.9% vs. 16.4%; p0.036) and acute kidney injury
(44.3% vs. 20.4%; p0.005), leading to an improved combined safety endpoint (40.0%
vs. 22.6%; p0.042). Interestingly, there was an increase in arrhythmia (18.6% vs.
49.1%; p0.001) and permanent pacemaker implantation (21.4% vs. 41.8%; p0.014) in
the MCVAT group. There were no differences in the event of embolization (7.1% vs.
12.7%; p0.293) or moderate-severe aortic regurgitation (5.7% vs. 5.7%; p0.990).
Furthermore, there was no difference in device success (90.0% vs. 85.5%; 0.438).
Conclusions: The MCVAT has improved safety endpoints compared to MCV, probably
due to the learning curve. However, there is a higher rate of arrhythmia and PPM in this
group, possibly due to the introduction of the 31 mm valve. Longer term follow-up and
larger patient numbers are required.
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Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe
aortic stenosis (AS) that is increasingly performed as a bridge to transcatheter aortic valve
replacement. We investigated the independent predictors of vascular complications in AS
patients who underwent BAV.
Methods: We performed a retrospective review of consecutive patients who undergoing
non-emergent, retrograde BAV at two high-volume US centers. We analyzed baseline and
procedural characteristics as well as in-hospital outcomes according to the presence or
absence of vascular complications, as classified by the Vascular Academic Research
Consortium (VARC). Net adverse clinical events (NACE) were defined as composite of
mortality, myocardial infarction, stroke and major bleeding.
Results: Among 428 BAV patients, the average age was 83 9 years and 30 (7.0%) had
vascular complications. Patients with vs. without vascular complications had higher rates
of myocardial infarction (13.3% vs. 2.5%; p0.001), stroke (6.7% vs. .03%; p0.001),
and NACE (33.3% vs. 9.8%; p0.001). Multivariable adjusted predictors of vascular
complications are shown in the Figure.
Conclusions: In this large registry of BAV patients, pre-closure failure, thrombocyto-
penia and concurrent PCI were associated withincreased risk of vascular complications in
patients undergoing BAV.
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Background: Transcatheter aortic valve replacement (TAVR) is the method of choice in
inoperable patients with severe aortic stenosis and is gaining increasing importance in
high risk patients and intermediate risk patients with additional critical comorbidities or
frailty. Two methods of access were used, transfemoral (TF) or transapical (TA), and
baseline characteristics, clinical outcomes and mortality to three years were evaluated in
both groups. Patient selection for TA or TF was made after consensus between
interdisciplinary heart team members. All procedures were performed in a hybrid OR by
a dedicated TAVR team.
Methods: Group I: TA in 413 patients (SAPIEN THV: 402, Symetis Acurate: 11), Group
II: TF in 587 patients (SAPIEN THV: 399, CoreValve: 188); from 5/08 to 04/12 in a
single center heart team.
Results: The mean age in TA group was 81.0 years and in TF 81.6 years, p0.3. The TA
group had more patients with peripheral artery disease (22.0% vs 10.9%), coronary artery
disease (64.4% vs 58.3%), carotid stenosis (23.2% vs 15. 7%), redo-operation (25.7% vs
14.8%) and neurological dysfunction (14.8% vs 10.4%) than in TF (all p0.05). In TF
more patients were seen with pulmonary hypertension (22.0% vs 15.5%, p0.05). The
mean EuroSCORE I in TA was 24.2% and in TF 22.3% (p0.007). Mortality at three
years in TA was 33.7% and 27.3% in TF.
Conclusions: With a dedicated, experienced heart team in a hybrid OR, patients with
severe aortic stenosis can be treated with similar rates of mortality regardless of approach
and despite the fact that one group has significantly more comorbidities.
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